Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) EBITDA Margin (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed EBITDA Margin for 4 consecutive years, with 2415.68% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin fell 86502.0% to 2415.68% in Q3 2025 year-over-year; TTM through Sep 2025 was 2666.93%, a 49420.0% decrease, with the full-year FY2024 number at 2310.92%, down 53113.0% from a year prior.
  • EBITDA Margin was 2415.68% for Q3 2025 at Orchestra BioMed Holdings, down from 2318.66% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 661.55% in Q1 2022 to a low of 6403.56% in Q4 2024.
  • A 4-year average of 2251.39% and a median of 2055.91% in 2024 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: plummeted -398212bps in 2023, then surged 162285bps in 2024.
  • Orchestra BioMed Holdings' EBITDA Margin stood at 884.68% in 2022, then crashed by -450bps to 4866.79% in 2023, then plummeted by -32bps to 6403.56% in 2024, then surged by 62bps to 2415.68% in 2025.
  • Per Business Quant, the three most recent readings for OBIO's EBITDA Margin are 2415.68% (Q3 2025), 2318.66% (Q2 2025), and 2162.44% (Q1 2025).